Anaplastic lymphoma kinase (ALK) fusion is an important molecular subtype of non–small-cell lung cancer, and patients who have ALK fusion can be highly sensitive to ALK tyrosine kinase inhibitors. Different ALK fusions showed different sensitivities to ALK tyrosine kinase inhibitors. EML4-ALK (E6; A18) fusion showed resistance to crizotinib in a 48-year-old male patient with lung adenocarcinoma. READ ARTICLE
Clinical Lung Cancer DOI:10.1016/j.cllc.2020.04.014
Authors: Xiaofeng Chen, Guohong Zhao, Peilin Zhong, Min Zhang, Rongrong Chen, Derong Zhang
